NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Antimicrobial Health Technology Evaluation

Cefiderocol for treating severe aerobic Gram-negative bacterial infections

Draft scope

Draft evaluation objective
To assess the value of cefiderocol to the NHS in England for treating severe aerobic Gram-negative bacterial infections.

The project
This health technology evaluation is part of a project to test new payment models for antimicrobials. The payment discussions between NHS England & NHS Improvement and the manufacturer of cefiderocol will be informed by this evaluation. These payments will be based on the value of cefiderocol to the NHS in England, and not linked to the volumes sold. The approach to value assessment is set out in the 2018 EEPRU report1 and in the Evaluation Framework. If the discussion between NHS England & NHS Improvement and the manufacturer is successful, they will enter into a 3-year contract, with an option to extend for up to another 7 years, during which the manufacturer will receive an annual, value-based payment.

Background
Antimicrobial resistance develops when microorganisms, like bacteria and fungi, adapt and become immune to the drugs designed to treat them. Multidrug-resistant bacteria can spread rapidly within both hospitals and community settings, further contributing to heightened resistance and antimicrobial use. Antimicrobial stewardship guidelines aim to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

The World Health Organisation (WHO) maintains a list of priority pathogens where, due to the development of resistance, new antimicrobials are urgently needed. The pathogens that the WHO deems ‘critical’ priorities are:

- carbapenem-resistant Acinetobacter baumannii
- carbapenem-resistant Pseudomonas aeruginosa
- carbapenem-resistant, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (including: Klebsiella pneumonia, Escherichia coli, and species of Enterobacter, Serratia, Proteus, Providencia and Morganella).

These pathogens are multidrug-resistant Gram-negative bacteria that can cause severe infections in secondary care settings, such as pneumonia and bloodstream infections (bacteraemia), that can often be fatal.4,5

In secondary care settings, Public Health England and NICE guidance recommend prescribing according to the ‘Start Smart, Then Focus’ algorithm. For severe and life-threatening infections, this means initiating treatment with an effective antimicrobial within 1 hour of diagnosis and obtaining cultures prior to starting therapy if possible.
Then at clinical review (48-72 hours later) microbiology should lead to a decision either: (1) to stop treatment, (2) switch to oral antimicrobials, (3) change to other IV antimicrobial, (4) continue treatment, or (5) switch to outpatient parenteral antibiotic therapy (OPAT).

The technology
Cefiderocol (Fetroga, Shionogi) is a siderophore cephalosporin that binds to penicillin binding proteins, inhibiting bacterial peptidoglycan cell wall synthesis and causing cell lysis and death. It is given intravenously.

Cefiderocol received a marketing authorisation in April 2020 for treating infections due to aerobic Gram-negative organisms in adults with limited treatment options.

It has been studied in clinical trials compared with either dual therapy imipenem and cilastatin, meropenem or ‘best alternative treatment’ in hospitalised adults with serious infections caused by gram-negative bacteria. Two of the trials included people in whom multi-drug resistant infection was suspected, and one trial included people only if carbapenem-resistance had been confirmed. The following types of infection were included in the studies:

- complicated urinary tract infections
- hospital-acquired pneumonia
- ventilator-associated pneumonia
- healthcare-associated pneumonia
- sepsis and bacteraemia.

In vitro studies suggested that cefiderocol might be efficacious against Achromobacter species, Acinetobacter baumannii complex, Burkholderia cepacia complex, Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Enterobacter cloacae complex, Klebsiella (Enterobacter) aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Serratia species, Pseudomonas aeruginosa, aSerratia marcescens and Stenotrophomonas maltophilia.

<table>
<thead>
<tr>
<th>Intervention(s)</th>
<th>Cefiderocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population(s)</td>
<td>People receiving treatment in secondary or tertiary care settings in whom resistant aerobic Gram-negative infection is suspected/confirmed</td>
</tr>
<tr>
<td>Comparators</td>
<td>Clinical management without cefiderocol, which may include:</td>
</tr>
<tr>
<td></td>
<td>• ceftazidime with avibactam</td>
</tr>
<tr>
<td></td>
<td>• ceftolozane with tazobactam</td>
</tr>
<tr>
<td></td>
<td>• colistimethate sodium (colistin), alone or in combination with fosfomycin or meropenem</td>
</tr>
<tr>
<td></td>
<td>• ertapenem</td>
</tr>
<tr>
<td></td>
<td>• gentamicin, alone or in combination with meropenem</td>
</tr>
</tbody>
</table>
### Appendix B

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
|  | • imipenem with cilastatin  
  • imipenem with cilastatin and relebactam  
  • meropenem  
  • meropenem with vaborbactam  
  • piperacillin with tazobactam  
  • tigecycline  
  • tobramycin, alone or in combination with meropenem  |

#### Outcomes

The outcome measures to be considered include:

- All-cause mortality
- 90-day mortality
- Clinical cure (complete resolution of signs/symptoms of the index infection such that no further antimicrobial therapy was needed)
- Microbiologic eradication
- Emergence of resistance
- Hospital days
- Intensive care unit (ICU) days
- Readmission date within 90 days of treatment
- Health-related quality of life
- Adverse events

#### Economic analysis

The NICE guide to the methods for technology appraisals (2013) will be followed where possible, with the following adaptations.

The aim of the analysis will be to estimate the value of cefiderocol to the NHS expressed under the stewardship scenario that generates the highest net health benefit to the NHS.

Within the timescale and resources assigned, it is unlikely to be possible to undertake detailed economic modelling for all pathogens/clinical syndrome combinations. The evaluation will include one or more “primary” indications for detailed study together with additional indications that need to be considered but where bespoke economic models will not be developed. For these additional indications a summary of relevant clinical and health economic information will be provided. Estimates of value to the NHS in England need to take account of the primary and additional indications.

The economic analysis outputs will be, wherever feasible, expressed in population net health benefits as measured in quality-adjusted life years. Population net health benefit should be estimated over the full time horizon of the economic model and options presented for assigning an
appropriate proportion of the total value to a potential 10-year contract period.

In the base-case analysis a threshold of £20,000 per quality-adjusted life year should be used for the calculation of net health benefits.

For antimicrobials, the evaluation will include consideration of additional elements of value as set out in the Evaluation Framework. These include diversity value, transmission value, enablement value, spectrum value, and insurance value.

Several stewardship strategies might need to be modelled and compared (e.g. rotation of antimicrobials, mixing protocols, reserving cefiderocol until testing reveals specific resistance patterns) to identify the optimal usage scenario.

Other considerations

Guidance will include consideration of the optimal stewardship scenarios.

Related NICE recommendations and NICE Pathways

**Related Guidelines:**

**Related Quality Standards:**
- Antimicrobial stewardship (2016) NICE quality standard 121

**Related NICE evidence summaries:**
- Antimicrobial prescribing: cefiderocol (2020) NICE evidence summary 31

Related National Policy

The NHS Long Term Plan, 2019. [NHS Long Term Plan](https://www.nhs.uk/longtermplan/)
- UK 20-year vision for antimicrobial resistance (2019)
- UK 5-year action plan for antimicrobial resistance 2019 to 2024 (2019)
- Antimicrobial resistance (updated 2019)
- Antimicrobial Resistance: resource handbook (updated 2017)
- Antimicrobial stewardship: Start Smart, Then Focus (updated 2015)

Questions for consultation

1. Does the population reflect those that would be eligible to receive cefiderocol in the NHS in England?
Appendix B

1. Cefiderocol is indicated for treating people ‘with limited treatment options’. How is ‘limited treatment options’ defined in practice? Does it refer to severe infections where resistance is suspected/confirmed, or is there a differentiation between the two terms?

2. Which treatments are considered to be established clinical practice in the NHS for people with severe infections due to aerobic gram-negative bacteria where resistance is confirmed/suspected?

3. Do established treatments differ according to infection site in people with severe infections due to aerobic gram-negative bacteria where resistance is confirmed/suspected?

4. What criteria should be used to identify the “primary” indication(s) for the economic analysis?
   a. For example: unmet need, disease severity, absolute patient numbers, availability of alternative treatment(s). Are there any others?

   For an explanation of the “primary” indication(s), please refer to the ‘economic analysis’ section of the table above, and paragraphs 4.3 and 4.4 of the Evaluation Framework.

5. In which indication(s) is cefiderocol expected to have the highest value when considering the criteria listed under question 4?
   a. What are the most important comparators for this indication(s)?

6. What testing strategies are used in clinical practice for people with severe infections due to aerobic gram-negative bacteria where resistance is suspected?

7. Are the outcomes listed appropriate?

8. What stewardship scenarios are relevant to be considered in the analysis?

9. NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed evaluation and scope may need changing in order to meet these aims. In particular, please tell us if the proposed evaluation and scope:

   • could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which cefiderocol will be licensed;

   • could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;

   • could have any adverse impact on people with a particular disability or disabilities.

   Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.
10. To help NICE prioritise topics for additional adoption support, do you consider that there will be any barriers to adoption of this technology into practice? If yes, please describe briefly.

References


